scholarly journals TUMORAL MARKERS IN OVARIAN CANCER – A LITERATURE REVIEW

2015 ◽  
Vol 62 (1) ◽  
pp. 16-19
Author(s):  
Nicolae Bacalbasa ◽  
◽  
Alexandra Gireada ◽  
Irina Balescu ◽  
◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Literature Review ◽  
Diagnostic Test ◽  
Tumor Markers ◽  
Advanced Stage ◽  
Biological Behaviour ◽  
Early Stages ◽  
Cancer Diagnostic

Ovarian cancer is one of the most lethal malignancies due to an aggressive biological behaviour of a tumor usually diagnosed in an advanced stage of the disease. Due to the fact that important differences in terms of survival have been observed between cases diagnosed in early stages when compared to those in FIGO stages III-IV, attention was focused on establishing which is the most appropriate laboratory diagnostic test which could help the clinician to diagnose and treat the disease in a less advanced stage. This is a literature review of the most frequently used tumor markers and scores used in ovarian cancer diagnostic and follow up.

Fifth Alon Dembo Memorial Workshop: Case 3

2010 ◽  
Vol 20 (Suppl 2) ◽  
pp. S24-S26 ◽  
Author(s):  
Peter E. Schwartz
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Cancer Patient ◽  
Recurrent Ovarian Cancer ◽  
Ca 125 ◽  
Advanced Stage ◽  
Recurrent Cancer ◽  
Treatment Regimens ◽  
Platinum Sensitive ◽  
Very High

Background:OVO5/EORTC 55855, a study punitively refuting the value of CA-125 in the follow-up of ovarian cancer patients, has many deficiencies, including a heterogeneous ovarian cancer patient population, no control of initial treatment regimens, and no control of subsequent surgery or chemotherapeutic management for recurrence. Recent studies suggest a role for prompt surgery in selected cases of recurrent ovarian cancer with CA-125 elevations, a role for tamoxifen in managing rising CA-125 levels in patients without evidence of disease and the use of platinum doublets for treating recurrent platinum-sensitive disease, none of which were incorporated into OVo5/EORTC 55955.Case:A patient with advanced stage ovarian cancer presenting with a CA-125 level of 2000 U/mL, who is initially treated with surgery followed by chemotherapy and has a normal CT scan and normal CA-125 at completion of her initial chemotherapy.Conclusion:This patient remains at a very high risk for recurrence. I would continue to monitor this patient with serial CA-125 levels to identify recurrent cancer and consider initiating treatment before it is clinically obvious.

scholarly journals The surgical treatment of thoracic metastases in ovarian cancer

2015 ◽  
Vol 10 (2) ◽  
pp. 132-136 ◽  
Author(s):  
Alice SAVESCU ◽  
◽  
Irina BALESCU ◽  
Nicolae BACALBASA ◽  
◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Surgical Treatment ◽  
Literature Review ◽  
Surgical Procedures ◽  
Complete Cytoreduction ◽  
Advanced Stage ◽  
Lymphatic Route

Ovarian cancer still represents one of the most aggressive malignancies affecting women worldwide. Unfortunately many patients are still diagnosed in an advanced stage of the disease when distal metastases are already present. When it comes to thoracic involvement in advanced stage ovarian cancer, this may develop via peritoneal, hematogenous and lymphatic route. This is a literature review of the most commonly seen involvements in ovarian cancer and of the most appropriate surgical procedures which might be performed in order to increase the rate of complete cytoreduction.

Practice patterns in post-treatment surveillance in patients with primary epithelial ovarian cancer

2020 ◽  
pp. ijgc-2020-001522
Author(s):  
Joseph DeMari ◽  
Monica Hagan Vetter ◽  
Shruthi Chandra ◽  
John L Hays ◽  
Ritu Salani
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Practice Patterns ◽  
Early Stage ◽  
Gynecologic Oncology ◽  
Complete Response ◽  
Response To Therapy ◽  
Primary Therapy ◽  
Advanced Stage

BackgroundThe Society of Gynecologic Oncology created guidelines to standardize cost-effective clinical surveillance for detection of recurrence of gynecologic cancers.ObjectiveTo determine practice patterns for surveillance of primary ovarian cancer after complete response to therapy and to identify the percentage of clinicians who follow the surveillance guidelines endorsed by the Society of Gynecologic Oncology.MethodsA single-institution retrospective cohort study was conducted including patients with epithelial ovarian cancer with a complete response to primary therapy between January 2012 and December 2016. Patients were excluded if they were participating in clinical trials that required routine imaging. Data on surveillance and recurrence were collected. Descriptive statistics as well as Fisher’s exact test and chi-square test were performed due to the exploratory nature of the study.ResultsA total of 184 patients met the inclusion criteria. Median follow-up for the cohort was 37 months (range 6–80). Surveillance was completed in compliance with Society of Gynecologic Oncology guidelines in 78% of patients. Of 39 visits that were non-compliant, 44% (17) were patient initiated (scheduling conflict, missed appointment), 15% (6) were due to the provider intentionally scheduling alternative follow-up, while 41% (16) were off schedule due to problem visits (patient complaint of symptoms). Patients with early-stage cancers were more likely than advanced-stage patients to be non-compliant (33% vs 15%, p=0.006). Patients with non-serous histologies had a higher frequency of non-compliance (31% vs 16%, p=0.035). When stratified by early versus advanced stage, there was no difference in progression-free survival or overall survival based on compliance.ConclusionsOverall, there was a relatively high rate of compliance with Society of Gynecologic Oncology surveillance guidelines for patients with epithelial ovarian cancer. Patients with non-serous histologies and patients with early-stage disease had a higher rate of non-compliance, and these patients may represent special groups that would benefit from additional survivorship education.

scholarly journals Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer

Cancer ◽  
2010 ◽  
Vol 116 (6) ◽  
pp. 1476-1484 ◽  
Author(s):  
Gisele A. Sarosy ◽  
Mahrukh M. Hussain ◽  
Michael V. Seiden ◽  
Arlan F. Fuller ◽  
Najmosama Nikrui ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Poor Prognosis ◽  
Initial Therapy ◽  
Advanced Stage ◽  
Phase 2 ◽  
Phase 2 Study

scholarly journals Prospective study of the role of HE4 and CA125 in treatment and follow-up in ovarian cancer patients

2020 ◽  
Vol 11 (3) ◽  
pp. 185-190
Author(s):  
Ann-Lisbeth Liest MD ◽  
Ahmed Shaker Omran ◽  
Rasmus Mikiver ◽  
Per Rosenberg ◽  
Srinivas Uppugunduri
Keyword(s):  
Ovarian Cancer ◽  
Tumor Markers ◽  
Surgical Intervention ◽  
Gynecological Cancer ◽  
Response To Treatment ◽  
Peritoneal Cancer ◽  
Reference Limit ◽  
Primary Surgery

Introduction: Epithelial Ovarian Cancer, tubal- and peritoneal cancer (EOC) is still the major cause of death in gynecological cancer. The outcome of primary surgery is an important prognostic factor. The primary aim of this study was to study the utility of HE4 and CA125 in monitoring the response of chemotherapy during treatment and in predicting prognosis and recurrence during follow-up. We have also evaluated the role of HE4 as a predictor of the result of surgical intervention. Methods: Seventy-eight patients scheduled for chemotherapy were monitored with serum HE4 and CA125 during treatment and follow-up. In 39 patients samples for tumor markers were also obtained prior to surgical intervention. Results: Both HE4 and CA125 decreased in response to treatment. PFS and OS were strongly dependent on HE4 levels prior to start of chemotherapy with significantly prolonged PFS and OS when HE4 levels were under upper reference limit of 82pmol/L (P=0.018 resp. P<0.001). The levels of HE4 correlated with primary surgical outcome with significantly lower postoperative HE4 in the radically operated group (P<0.001). An increase in HE4 and/or CA125, signals a recurrence 3-6months before diagnosis. Median levels for both HE4 and AC125 before start, during and at the end of treatment were significantly higher for platinum resistant patients (P<0.005). Conclusion: Both tumor markers are valuable in monitoring the response of chemotherapy as well as in predicting recurrence during follow-up. Postoperative HE4 holds promise as an objective marker to evaluate the result of surgery and is highly predictive for future prognosis.

scholarly journals Cytoreductive surgery for advanced stage ovarian cancer in the second trimester of pregnancy—a case report and literature review

Medicine ◽  
2020 ◽  
Vol 99 (29) ◽  
pp. e21127
Author(s):  
Nicolae Bacalbaşa ◽  
Irina Bălescu ◽  
Mihaela Vîlcu ◽  
Simona Dima ◽  
Laura Iliescu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Case Report ◽  
Literature Review ◽  
Cytoreductive Surgery ◽  
Advanced Stage ◽  
Second Trimester
Sign in / Sign up

Export Citation Format

Share Document